IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.
Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market share, and strengthening the company's distribution network across North America.
"This promotion marks an exciting new chapter for InMode, led by a visionary leader with a proven commitment to cultivating talent and driving market excellence," said Moshe Mizrahy, CEO of InMode. "Dennison's extensive industry experience and inspirational leadership will be pivotal in advancing our strategic initiatives and accelerating growth, as part of our North American restructuring."
"I am honored to continue building on InMode's strong foundation," said Dennison. "Together, we will accelerate momentum in the North American market, deliver greater value to our partners, and set new standards of excellence across the aesthetic and medical device industry."
Before joining InMode, Dennison held multiple leadership positions at Cynosure, where he consistently exceeded sales targets and built high-performing teams that drove significant revenue growth.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Press Contact:
Behrman Cesa Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
MS-IR LLC
Miri Segal – Scharia
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$14.63 |
| Daily Change: | -0.06 -0.41 |
| Daily Volume: | 852,410 |
| Market Cap: | US$924.760M |
September 02, 2025 July 30, 2025 April 28, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load